Plus Therapeutics (PSTV)
NASDAQ:PSTV
Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume69.06K
Average Volume (3M)159.53K
Market Cap
$37.31M
Enterprise Value$11.79M
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 19, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume153,045
30 Day Avg. Volume159,529
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit2.45
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$38.00Price Target Upside6451.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.87
Revenue Forecast (FY)$6.04M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained gross margins near 94% indicate attractive unit economics for the radiotherapeutic platform. High product-level margins can support scalable commercialization, fund ongoing R&D per unit sold, and provide pricing flexibility — durable advantages once clinical approvals enable sales.
Low LeverageVery low debt reduces near-term balance-sheet pressure and interest burden, giving management flexibility to pursue clinical programs and partnerships without immediate refinancing risk. For a clinical-stage biotech, low leverage materially lowers solvency risk over the medium term.
Orphan Drug DesignationOrphan designation for REYOBIQ adds structural regulatory benefits—potential market exclusivity, tax credits and fee reductions—and strengthens the commercial and development pathway for pediatric CNS indications, improving long-term asset value and partnership/licensing prospects.
Bears Say
Sustained Cash BurnOperating and free cash flows are deeply negative, implying repeated external funding needs. Persistent cash burn at this scale versus minimal commercial receipts raises dilution and financing risk, constraining long-term execution unless offset by major financing, partnerships, or approvals.
Very Small, Declining RevenueRevenue remains minimal and declined year-over-year, leaving the company without meaningful product cash flows to sustain R&D or SG&A. This structural lack of recurring revenue increases dependence on capital markets or collaborators for durable program advancement.
Persistent Large Net LossesVery large and persistent net losses reflect a fundamental mismatch between expenses and revenue scale. Sustained negative margins limit internal reinvestment capacity and require continued external capital or strategic deals, making long-term profitability contingent on successful clinical commercialization.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $37.31M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 74 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (6451.72% Upside)
$38.00 (6451.72% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.84%
12-Months-Change
Fundamentals
Return on Equity
-198.48%
Trailing 12-Months
Asset Growth
65.20%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Stock 12 Month Forecast
Average Price Target
$38.00
▲(6451.72% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---